DK3045474T3 - Terapeutiske midler til behanlding af sygdomme, der er forbundet med uønsket celleproliferation - Google Patents

Terapeutiske midler til behanlding af sygdomme, der er forbundet med uønsket celleproliferation Download PDF

Info

Publication number
DK3045474T3
DK3045474T3 DK16155009.0T DK16155009T DK3045474T3 DK 3045474 T3 DK3045474 T3 DK 3045474T3 DK 16155009 T DK16155009 T DK 16155009T DK 3045474 T3 DK3045474 T3 DK 3045474T3
Authority
DK
Denmark
Prior art keywords
treatment
cell proliferation
diseases related
undesirable cell
therapeutic medicines
Prior art date
Application number
DK16155009.0T
Other languages
English (en)
Inventor
Suárez Joan Seoane
Prieto Silvia Peñuelas
Torres José Baselga
Original Assignee
Fundacio Privada Inst Catalana De Recerca I Estudis Avancats
Fundacio Privada Inst Dinvestigacio Oncològica De Vall Dhebron
Fundacio Privada Institut De Recerca Hospital Univ Vall Hebron
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fundacio Privada Inst Catalana De Recerca I Estudis Avancats, Fundacio Privada Inst Dinvestigacio Oncològica De Vall Dhebron, Fundacio Privada Institut De Recerca Hospital Univ Vall Hebron filed Critical Fundacio Privada Inst Catalana De Recerca I Estudis Avancats
Application granted granted Critical
Publication of DK3045474T3 publication Critical patent/DK3045474T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2093—Leukaemia inhibitory factor [LIF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/248—IL-6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7115—Nucleic acids or oligonucleotides having modified bases, i.e. other than adenine, guanine, cytosine, uracil or thymine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7125—Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
DK16155009.0T 2009-04-03 2010-04-06 Terapeutiske midler til behanlding af sygdomme, der er forbundet med uønsket celleproliferation DK3045474T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ES200900928A ES2363358B1 (es) 2009-04-03 2009-04-03 Agentes terapéuticos para el tratamiento de enfermedades asociadas con una proliferación celular indeseable.
EP10713619A EP2414394A2 (en) 2009-04-03 2010-04-06 Therapeutic agents for the treatment of diseases associated with undesired cell proliferation

Publications (1)

Publication Number Publication Date
DK3045474T3 true DK3045474T3 (da) 2021-03-22

Family

ID=42342718

Family Applications (1)

Application Number Title Priority Date Filing Date
DK16155009.0T DK3045474T3 (da) 2009-04-03 2010-04-06 Terapeutiske midler til behanlding af sygdomme, der er forbundet med uønsket celleproliferation

Country Status (24)

Country Link
US (4) US10100112B2 (da)
EP (2) EP3045474B1 (da)
JP (5) JP6207836B2 (da)
KR (6) KR20220035978A (da)
CN (2) CN102574918A (da)
AU (1) AU2010233791B2 (da)
BR (1) BRPI1015369A2 (da)
CA (1) CA2757680C (da)
CY (1) CY1124148T1 (da)
DK (1) DK3045474T3 (da)
EA (1) EA201101450A1 (da)
ES (2) ES2363358B1 (da)
HR (1) HRP20210352T1 (da)
HU (1) HUE054196T2 (da)
IL (1) IL215467A (da)
LT (1) LT3045474T (da)
MX (1) MX336903B (da)
PL (1) PL3045474T3 (da)
PT (1) PT3045474T (da)
SG (2) SG10202010568RA (da)
SI (1) SI3045474T1 (da)
SM (1) SMT202100153T1 (da)
WO (1) WO2010115868A2 (da)
ZA (1) ZA201107215B (da)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2615491C (en) * 2005-07-19 2016-11-29 Stemgen S.P.A. Inhibition of the tumorigenic potential of tumor stem cells by lif and bmps
EP2371860A1 (en) 2010-04-05 2011-10-05 Fundació Privada Institut d'Investigació Oncològica de Vall d'Hebron Antibody recognising human leukemia inhibitory factor (LIF) and use of anti-LIF antibodies in the treatment of diseases associated with unwanted cell proliferation
JP2015071566A (ja) * 2013-10-03 2015-04-16 住友ベークライト株式会社 Ｆｇｆ４遺伝子増幅腫瘍の医薬組成物
WO2015136557A2 (en) * 2014-03-11 2015-09-17 Godavari Biorefineries Limited Cancer stem cell targeting compounds
KR102762243B1 (ko) * 2014-06-30 2025-02-05 알토 바이오사이언스 엘엘씨 Il-15-베이즈드 분자 및 이의 사용 방법
EP3191129A4 (en) * 2014-09-10 2018-03-14 The Regents of The University of California TARGETING K-RAS-MEDIATED SIGNALING PATHWAYS AND MALIGNANCY BY ANTI-hLIF ANTIBODIES
EP3067422B1 (en) * 2015-03-13 2024-07-31 Sabanci Üniversitesi Ct-1 inhibitors
EP3273983B1 (en) 2015-03-23 2021-05-05 Evestra, Inc. Novel cytotoxic agents that preferentially target leukemia inhibitory factor (lif) for the treatment of malignancies and as new contraceptive agents
EP3173483A1 (en) 2015-11-27 2017-05-31 Fundació Privada Institut d'Investigació Oncològica de Vall-Hebron Agents for the treatment of diseases associated with undesired cell proliferation
US10583191B2 (en) 2016-12-19 2020-03-10 Mosaic Biomedicals Slu Antibodies against LIF and uses thereof
SI3555132T1 (sl) 2016-12-19 2024-04-30 Medimmune Limited Protitelesa proti LIF in njihove uporabe
WO2019220204A2 (en) * 2018-05-14 2019-11-21 Mosaic Biomedicals Slu Antibodies against lif and dosage forms thereof
AU2019291305B2 (en) * 2018-06-18 2024-03-21 Fundacio Privada Institucio Catalana de Recerca i Estudis Avancats Methods for improving response to anti-LIF antibody treatment in individuals with cancer
SG11202012576QA (en) * 2018-06-18 2021-01-28 Medimmune Ltd Combination of lif inhibitors and platinum-based antineoplastic agents for use in treating cancer
WO2020056349A2 (en) * 2018-09-13 2020-03-19 Evestra, Inc. Lif/lifr antagonist oncology and nonmalignant diseases
MX2021012163A (es) * 2019-04-17 2022-01-31 Univ Hiroshima Agente terapeutico para cancer urologico que se caracteriza por ser administrado con un inhibidor de il-6 y un inhibidor de ccr2 en combinacion.
CN111020030A (zh) * 2019-12-03 2020-04-17 中山大学 一种骨肉瘤干细胞标志物及其应用、试剂盒
EP3988116A1 (en) * 2020-10-23 2022-04-27 Consejo Superior De Investigaciones Científicas (CSIC) Methods and compositions for the treatment of hematologic malignancies

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4902505A (en) 1986-07-30 1990-02-20 Alkermes Chimeric peptides for neuropeptide delivery through the blood-brain barrier
US4987071A (en) 1986-12-03 1991-01-22 University Patents, Inc. RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
AU600575B2 (en) 1987-03-18 1990-08-16 Sb2, Inc. Altered antibodies
US4904582A (en) 1987-06-11 1990-02-27 Synthetic Genetics Novel amphiphilic nucleic acid conjugates
ATE115999T1 (de) 1987-12-15 1995-01-15 Gene Shears Pty Ltd Ribozyme.
US5176996A (en) 1988-12-20 1993-01-05 Baylor College Of Medicine Method for making synthetic oligonucleotides which bind specifically to target sites on duplex DNA molecules, by forming a colinear triplex, the synthetic oligonucleotides and methods of use
US5256775A (en) 1989-06-05 1993-10-26 Gilead Sciences, Inc. Exonuclease-resistant oligonucleotides
US5264564A (en) 1989-10-24 1993-11-23 Gilead Sciences Oligonucleotide analogs with novel linkages
GB9004890D0 (en) * 1990-03-05 1990-05-02 Heath John K Leukaemia inhibitory factor
EP0940468A1 (en) 1991-06-14 1999-09-08 Genentech, Inc. Humanized antibody variable domain
JPH05304986A (ja) * 1992-04-28 1993-11-19 Tosoh Corp ｇｐ１３０蛋白質に対するモノクロ−ナル抗体
AU4231393A (en) * 1992-05-08 1993-12-13 Genentech Inc. Antibodies to leukemia inhibitory factor
GB9413316D0 (en) 1994-07-01 1994-08-24 Cancer Res Campaign Tech Novel proteins
US6251588B1 (en) 1998-02-10 2001-06-26 Agilent Technologies, Inc. Method for evaluating oligonucleotide probe sequences
US20050147609A1 (en) 1998-05-15 2005-07-07 Genentech, Inc. Use of anti-IL-17 antibody for the treatment of cartilage damaged by osteoarthritis
KR101077001B1 (ko) 1999-01-15 2011-10-26 제넨테크, 인크. 효과기 기능이 변화된 폴리펩티드 변이체
AU776790B2 (en) * 1999-02-12 2004-09-23 Lexigen Pharmaceuticals Corporation Methods for treatment of tumors and metastases using a combination of anti-angiogenic and immuno therapies
US6110462A (en) 1999-03-03 2000-08-29 The Scripps Research Institute Enzymatic DNA molecules that contain modified nucleotides
US7084257B2 (en) 2001-10-05 2006-08-01 Amgen Inc. Fully human antibody Fab fragments with human interferon-gamma neutralizing activity
AU2003218456A1 (en) 2002-04-01 2003-10-20 Human Genome Sciences, Inc. Antibodies that specifically bind to gmad
EP1576131A4 (en) * 2002-08-15 2008-08-13 Genzyme Corp EXPRESSION PATTERN IN BRAIN DENTHELIC CELLS
US20060078533A1 (en) * 2004-10-12 2006-04-13 Omoigui Osemwota S Method of prevention and treatment of aging and age-related disorders including atherosclerosis, peripheral vascular disease, coronary artery disease, osteoporosis, arthritis, type 2 diabetes, dementia, alzheimer's disease and cancer
US7361740B2 (en) 2002-10-15 2008-04-22 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
WO2004067778A2 (en) * 2003-01-28 2004-08-12 University Of South Florida Differentially expressed genes in large granular lymphocyte leukemia
WO2005030803A1 (en) * 2003-09-29 2005-04-07 The Walter And Eliza Hall Institute Of Medical Research Therapeutic molecules
AU2005248147A1 (en) * 2004-05-11 2005-12-08 Alphagen Co., Ltd. Polynucleotides for causing RNA interference and method for inhibiting gene expression using the same
JP2012501188A (ja) * 2008-08-29 2012-01-19 ジェネンテック， インコーポレイテッド Ｖｅｇｆ非依存性腫瘍についての診断薬および治療
EP2371860A1 (en) * 2010-04-05 2011-10-05 Fundació Privada Institut d'Investigació Oncològica de Vall d'Hebron Antibody recognising human leukemia inhibitory factor (LIF) and use of anti-LIF antibodies in the treatment of diseases associated with unwanted cell proliferation
US10583191B2 (en) * 2016-12-19 2020-03-10 Mosaic Biomedicals Slu Antibodies against LIF and uses thereof

Also Published As

Publication number Publication date
CY1124148T1 (el) 2022-05-27
SI3045474T1 (sl) 2021-07-30
WO2010115868A3 (en) 2011-02-03
CA2757680A1 (en) 2010-10-14
JP2012522756A (ja) 2012-09-27
EP3045474A2 (en) 2016-07-20
ZA201107215B (en) 2012-12-27
JP7197665B2 (ja) 2022-12-27
JP2022031742A (ja) 2022-02-22
SMT202100153T1 (it) 2021-05-07
KR20200078668A (ko) 2020-07-01
US11999782B2 (en) 2024-06-04
KR20170121319A (ko) 2017-11-01
KR20220035978A (ko) 2022-03-22
JP2020090522A (ja) 2020-06-11
HRP20210352T1 (hr) 2021-05-28
JP6207836B2 (ja) 2017-10-04
CN102574918A (zh) 2012-07-11
CN107964043A (zh) 2018-04-27
SG175032A1 (en) 2011-11-28
JP2016040255A (ja) 2016-03-24
MX336903B (es) 2016-02-04
LT3045474T (lt) 2021-05-10
ES2864639T3 (es) 2021-10-14
US20120114671A1 (en) 2012-05-10
EP3045474A3 (en) 2016-09-28
PT3045474T (pt) 2021-03-22
PL3045474T3 (pl) 2021-08-09
CA2757680C (en) 2021-11-02
MX2011010425A (es) 2012-03-06
US20190211095A1 (en) 2019-07-11
US20240400667A1 (en) 2024-12-05
WO2010115868A2 (en) 2010-10-14
IL215467A (en) 2016-06-30
SG10202010568RA (en) 2020-11-27
US10100112B2 (en) 2018-10-16
HUE054196T2 (hu) 2021-08-30
ES2363358B1 (es) 2012-06-21
ES2363358A1 (es) 2011-08-01
KR102373754B1 (ko) 2022-03-15
KR20190093691A (ko) 2019-08-09
KR20180079470A (ko) 2018-07-10
AU2010233791A1 (en) 2011-11-03
KR20120100703A (ko) 2012-09-12
EP2414394A2 (en) 2012-02-08
BRPI1015369A2 (pt) 2021-06-29
EA201101450A1 (ru) 2012-04-30
JP2019006784A (ja) 2019-01-17
IL215467A0 (en) 2011-12-29
AU2010233791B2 (en) 2016-01-21
US20200385455A1 (en) 2020-12-10
EP3045474B1 (en) 2021-01-13

Similar Documents

Publication Publication Date Title
DK3045474T3 (da) Terapeutiske midler til behanlding af sygdomme, der er forbundet med uønsket celleproliferation
LTC2785706I2 (lt) Pakeistieji 4-fenil-piridinai, skirti su nk-receptoriumi susijusių ligų gydymui
DK2470199T3 (da) Dosisoptrapning enzymerstatningsterapi til behandling af mangel på sur sphingomyelinase
DK2451482T3 (da) Kombinationsterapi til behandlingen af diabetes
DK2421879T3 (da) Nye 7-deazapurinnukleotider til terapeutiske anvendelser
DK3192520T3 (da) Terapeutiske midler til reducering af niveauerne af parathyreoideahormon
DK3470063T3 (da) Farmaceutiske sammensætninger til behandling af cftr-medierede sygdomme
LT2558105T (lt) Bardoksolono metilas, skirtas nutukimo gydymui
DK3744313T3 (da) Excipienser til nikotin-indeholdende terapeutiske sammensætninger
DK2504005T3 (da) Anvendelse af 1,3-diphenylprop-2-en-1-on-derivater til behandling af lever-sygdomme
DK2506712T3 (da) Morfinanderivater til behandling af lægemiddeloverdosering
IL233313A0 (en) Composition of novel carbohydrate drug for treatment of human diseases
DK2627345T3 (da) Formuleringer til behandling af sygdomme i de øvre luftveje
PL2435825T3 (pl) Sposoby leczenia chorób
PL2582366T3 (pl) Kombinacja farmaceutyczna do leczenia bólu
DK2538986T3 (da) Intraartikulært supplement til anvendelse til behandling af ledsygdomme og -skader
DK2285808T3 (da) Spiroindolderivater til behandling af parasitsygdomme
DK3338777T3 (da) Ester-pro-drugs af [3-(1-(1h-imidazol-4-yl)ethyl)-2-methylphenyl] methanol til behandling af nethindesygdomme
CO6801718A2 (es) Composición terapéutica para el tratamiento de glioblastoma
GB0906159D0 (en) Drug combination for the treatment of proteostatic diseases
GB0904427D0 (en) Treatment of diseases related to hyperactivity of the complement system
DK3061766T3 (da) Sammensætninger og fremgangsmåder til behandlingen af sygdomme der involverer epitelcelleapoptose
EE201300004A (et) Kombineeritud ravimkoostis sdame-veresoonkonnaga seotud haiguste v?i seisundite raviks
DK2561890T3 (da) Fremgangsmåde til fremstilling af medikamenter til bekæmpelse af tumorer
EP2604264A4 (en) PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF VIRUS DISEASES